Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 3

Conditions

Uterine Cervical Neoplasms 4Condylomata Acuminata 4Anus Neoplasms 4Vulvar Neoplasms 3Papillomavirus Infections 3Vaginal Neoplasms 2Colonic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Breast Neoplasms 1Anal Canal Carcinoma 1Adenoviridae Infections 1

Interventions

Fluorouracil 26Radiotherapy 18Mitomycin 17Cisplatin 12Capecitabine 12pembrolizumab 10Magnetic Resonance Spectroscopy 9Cyclophosphamide 9Radiation 8Paclitaxel 8Biopsy 8fludarabine 7Specimen Handling 7Nivolumab 7Drug Therapy 7Carboplatin 7Surveys and Questionnaires 6Cetuximab 6Papillomavirus Vaccines 5dehydroftorafur 4aldesleukin 4Vaccines 4Radiotherapy, Intensity-Modulated 4Observation 4Irinotecan 4Watchful Waiting 3Taxes 3Oxaliplatin 3Light Coagulation 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Anus Neoplasms × Vaccines × Gastrointestinal × Clear all
NCT06866574 2025-07-31

A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males

Xiamen University

Phase 3 Active not recruiting
9,300 enrolled
Gastrointestinal

Anus Neoplasms, Condylomata Acuminata

NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 2 Completed
780 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Beijing Health Guard Biotechnology, Inc

Phase 3 Active not recruiting
2,750 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡